Persistence of gadolinium contrast enhancement in CSF: a possible harbinger of gadolinium neurotoxicity?
Hui
F K
FK
Mullins
M
M
D001921:Brain / Q000473:pathology*; D002555:Cerebrospinal Fluid / Q000166:cytology*; D003287:Contrast Media / Q000009:adverse effects*; D005682:Gadolinium / Q000009:adverse effects*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000009:adverse effects*; D020258:Neurotoxicity Syndromes / Q000175:diagnosis* / Q000209:etiology*; D009498:Neurotoxins / Q000009:adverse effects; D018570:Risk Assessment
D003287:Contrast Media; D009498:Neurotoxins; D005682:Gadolinium